Publications by authors named "E Balleari"
Background: Azacitidine (AZA) is the standard treatment for myelodysplastic syndromes (MDS); however, many patients prematurely stop therapy and have a dismal outcome.
Methods: The authors analyzed outcomes after AZA treatment for 402 MDS patients consecutively enrolled in the Italian MDS Registry of the Fondazione Italiana Sindromi Mielodisplastiche, and they evaluated the North American MDS Consortium scoring system in a clinical practice setting.
Results: At treatment discontinuation, 20.
Article Synopsis
- Myelodysplastic syndromes (MDS) are blood disorders leading to ineffective blood cell production and increased cell death, resulting in low blood cell counts.
- Mitochondria, which manage cell energy and can accumulate iron, were studied to understand their role in the altered energy metabolism found in MDS and how factors like iron overload affect this process.
- Findings indicated that MDS patients showed reduced energy production efficiency and higher oxidative stress, but iron chelation treatment improved some biochemical abnormalities in their cells, whereas similar treatments had lesser effects on healthy individuals.
Background: Erythropoiesis-stimulating agents effectively improve the hemoglobin levels in a fraction of anemic patients with myelodysplastic syndromes (MDS). Higher doses (HD) of recombinant human erythropoietin (rhEPO) have been proposed to overcome suboptimal response rates observed in MDS patients treated with lower "standard doses" (SD) of rhEPO. However, a direct comparison between the different doses of rhEPO is lacking.
View Article and Find Full Text PDF